RT Journal Article
SR Electronic
T1 Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1607
OP 1613
DO 10.21873/anticanres.15635
VO 42
IS 3
A1 OKADA, TAKURO
A1 FUSHIMI, CHIHIRO
A1 MATSUKI, TAKASHI
A1 OKAMOTO, ISAKU
A1 SATO, HIROKI
A1 KONDO, TAKAHITO
A1 TOKASHIKI, KUNIHIKO
A1 KISHIDA, TAKUMA
A1 ITO, TATSUYA
A1 YAMASHITA, GAI
A1 AIHARA, YUSUKE
A1 HANYU, KENJI
A1 KUSHIHASHI, YUKIOMI
A1 MASUBUCHI, TATSUO
A1 TADA, YUICHIRO
A1 MIURA, KOUKI
A1 HARADA, YUKI
A1 MOMIYAMA, KAHO
A1 YAMASHITA, TAKU
A1 OMURA, GO
A1 TAKAHASHI, HIDEAKI
A1 ORIDATE, NOBUHIKO
A1 TSUKAHARA, KIYOAKI
YR 2022
UL http://ar.iiarjournals.org/content/42/3/1607.abstract
AB Background/Aim: There are no real-world comparative data of nivolumab doses of 3 mg/kg and 240 mg/body for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We investigated the efficacy and safety of nivolumab in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) at different doses using real-world data. Patients and Methods: R/M SCCHN patients who received nivolumab were divided into the 3 mg/kg and 240 mg/body groups and retrospectively examined for efficacy and safety. Results: A total of 199 patients (3 mg/kg and 240 mg/body, 88 and 111 patients, respectively) were included. The 3 mg/kg vs. 240 mg/body groups had similar overall response rates (15% vs. 25, p=0.15), disease control rates (46% vs. 57%, p=0.15), overall survival (9.5 months vs. 10.9 months), and progression-free survival (3.7 months vs. 3.8 months, p=0.95). The incidence of immune-related adverse events was also similar in both groups. Conclusion: In R/M SCCHN patients, nivolumab showed similar efficacy and safety at doses of 3 mg/kg and 240 mg/body.